FM19G11

Research use only, not for human use.

Hypoxia inducible factor (HIF) α-subunit inhibitor (IC50 = 80 nM in hypoxia induced luciferase assay). Inhibits transcriptional activity of HIFα isoforms.

Hypoxia inducible factor (HIF) α-subunit inhibitor (IC50 = 80 nM in hypoxia induced luciferase assay). Inhibits transcriptional activity of HIFα isoforms. Directly regulates expression and inhibits transcriptional activity of pluripotency markers (Sox2 and Oct4) in rodent and human stem cells under hypoxic conditions, driving differentiation. Improves locomotion after severe spinal cord injury in mice, alone or in combination with transplantation of ependymal stem cells of the spinal cord. Also inhibits O6-methylguanine DNA methyltransferase (MGMT) via HIF1α pathway, under normal and hypoxic conditions in glioblastoma cell lines.(In Vitro):FM19G11 (500 nM) promotes oligodendrocyte differentiation under hypoxic conditions. FM19G11 (300 nM) significantly enhances the pro-apoptotic effect of temozolomide, whereas FM19G11 does not induce apoptosis. In hypoxic GBM-XD, hypoxic T98G, and normoxic T98G cells, FM19G11 (300 nM) significantly inhibited the mRNA level of O6-methylguanine DNA-methyltransferase via the HIF-1α pathway.(In Vivo):Intramedullary injection of FM19G11 improves locomotion in severe spinal cord injury and induces the expression of GAP43 and RIP at the injury.

HIF-1alpha/2alpha Inhibitor

Others

Other Targets

5-HT1B;5-HT1D

——

——

329932-55-0

463.4

C23H17N3O8

>98% (HPLC)

——

Cc1ccc(cc1)C(=O)COC(=O)c1cccc(NC(=O)c2ccc(cc2[N+]([O-])=O)[N+]([O-])=O)c1

——

(-20℃)

With Ice Pack

≥ 2 years